drugset / Trial / NCT00130975
Candesartan in the Prevention of Relapsing Atrial Fibrillation
Phase 3
Completed
200 enrolled
Asker & Baerum Hospital
AstraZeneca · collabHelse Ost · collabUllevaal University Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical cardioversion.
Timeline
- Start
- 2001-04
- Primary completion
- —
- Completion
- 2005-09
Publications
- Results Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007 Aug 9;120(1):85-91. doi: 10.1016/j.ijcard.2006.08.086. Epub 2006 Nov 17.
- Horjen AW, Seljeflot I, Berge T, Smith P, Arnesen H, Tveit A. Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation. Thromb J. 2017 Dec 28;15:30. doi: 10.1186/s12959-017-0153-1. eCollection 2017.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candesartan | Unknown | 16 mg | — |